{
  "trial_id": "NCT01190098",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "1 or 2 marketed AEDs for at least 4 weeks will be randomized in a double-blind, 4:1 scheme to LCM 400 mg/day or placebo, respectively.",
      "label": "met"
    },
    {
      "criterion": "LCM 400 mg/day or placebo, respectively. At the end of the Treatment Phase, subjects will have the option to enter an Extension Phase whereby they will receive LCM titrated to 400 mg/day.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Subject has a history of a moderate or severe sleep apnea (apnea-hypopnea index [AHI] > 15),",
      "label": "triggers"
    },
    {
      "criterion": "Subject is currently participating or has participated within the last 2 months in a trial of an investigational drug or experimental device.",
      "label": "unknown"
    }
  ],
  "notes": "Patient has history of severe intellectual disability, CHF, epilepsy. He had seizures at age 13 and was maintained on Dilantin and phenobarbital for 20 years without another seizure. Recently tapered off Dilantin.",
  "_meta": {
    "topic_id": "9",
    "trial_id": "NCT01190098",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}